GILD Gilead Sciences Inc. Loading... : Bullish and Bearish Analyst Opinions
From INCY earnings callsLoading chart...
Top Calls
Feed
12:00
Jul 28
Jul 28
Niktimbo is growing by gaining market share in third-line plus myelofibrosis, but the recent data from other companies like Gilead's momelotinib could heighten competition in this setting. — With a third of the market, Incyte faces direct competition from Gilead's momelotinib and possibly others; maintaining this share is key to the heme-onc portfolio's growth.
MED
About GILD Analyst Coverage
Buzzberg tracks GILD (Gilead Sciences Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Bill.